ProMeris

RSS
Withdrawn

This medicine's authorisation has been withdrawn

metaflumizone
MedicineVeterinaryWithdrawn
  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for ProMeris has been withdrawn at the request of the marketing authorisation holder.

български (BG) (217.29 KB - PDF)

View

español (ES) (192.56 KB - PDF)

View

čeština (CS) (217.67 KB - PDF)

View

dansk (DA) (191.94 KB - PDF)

View

Deutsch (DE) (193.36 KB - PDF)

View

eesti keel (ET) (191.37 KB - PDF)

View

ελληνικά (EL) (219.08 KB - PDF)

View

français (FR) (193.21 KB - PDF)

View

italiano (IT) (191.59 KB - PDF)

View

latviešu valoda (LV) (213.28 KB - PDF)

View

lietuvių kalba (LT) (214.74 KB - PDF)

View

magyar (HU) (212.15 KB - PDF)

View

Malti (MT) (218.75 KB - PDF)

View

Nederlands (NL) (191.68 KB - PDF)

View

polski (PL) (216.46 KB - PDF)

View

português (PT) (192.4 KB - PDF)

View

română (RO) (214.2 KB - PDF)

View

slovenčina (SK) (215.86 KB - PDF)

View

slovenščina (SL) (208.53 KB - PDF)

View

Suomi (FI) (191.92 KB - PDF)

View

svenska (SV) (191.72 KB - PDF)

View

Product information

български (BG) (389.52 KB - PDF)

View

español (ES) (328.73 KB - PDF)

View

čeština (CS) (374.1 KB - PDF)

View

dansk (DA) (330.12 KB - PDF)

View

Deutsch (DE) (340.98 KB - PDF)

View

eesti keel (ET) (336.16 KB - PDF)

View

ελληνικά (EL) (400.6 KB - PDF)

View

français (FR) (342.69 KB - PDF)

View

íslenska (IS) (332.3 KB - PDF)

View

italiano (IT) (310.69 KB - PDF)

View

latviešu valoda (LV) (368.86 KB - PDF)

View

lietuvių kalba (LT) (376.46 KB - PDF)

View

magyar (HU) (368.57 KB - PDF)

View

Malti (MT) (376.05 KB - PDF)

View

Nederlands (NL) (331.24 KB - PDF)

View

norsk (NO) (340.4 KB - PDF)

View

polski (PL) (391.6 KB - PDF)

View

português (PT) (331.45 KB - PDF)

View

română (RO) (368.38 KB - PDF)

View

slovenčina (SK) (386.11 KB - PDF)

View

slovenščina (SL) (371.43 KB - PDF)

View

Suomi (FI) (337.57 KB - PDF)

View

svenska (SV) (330.13 KB - PDF)

View
Latest procedure affecting product information: IB/0012
08/07/2015

български (BG) (190.37 KB - PDF)

View

español (ES) (144.19 KB - PDF)

View

čeština (CS) (184.81 KB - PDF)

View

dansk (DA) (144.38 KB - PDF)

View

Deutsch (DE) (146.91 KB - PDF)

View

eesti keel (ET) (144.06 KB - PDF)

View

ελληνικά (EL) (186.84 KB - PDF)

View

français (FR) (141.5 KB - PDF)

View

íslenska (IS) (141.82 KB - PDF)

View

italiano (IT) (144.6 KB - PDF)

View

latviešu valoda (LV) (189.21 KB - PDF)

View

lietuvių kalba (LT) (179.82 KB - PDF)

View

magyar (HU) (175.56 KB - PDF)

View

Malti (MT) (198.96 KB - PDF)

View

Nederlands (NL) (141.54 KB - PDF)

View

norsk (NO) (141.71 KB - PDF)

View

polski (PL) (163.63 KB - PDF)

View

português (PT) (144.35 KB - PDF)

View

română (RO) (142.48 KB - PDF)

View

slovenčina (SK) (181.1 KB - PDF)

View

slovenščina (SL) (174.66 KB - PDF)

View

Suomi (FI) (144.95 KB - PDF)

View

svenska (SV) (141.76 KB - PDF)

View

Product details

Name of medicine
ProMeris
Active substance
metaflumizone
International non-proprietary name (INN) or common name
metaflumizone
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) code
QP53AX25

Pharmacotherapeutic group

Ectoparasiticides for topical use, incl. insecticides

Therapeutic indication

Treatment and prevention of flea infestations (Ctenocephalides canis and C. felis) in cats. The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

Authorisation details

EMA product number
EMEA/V/C/000107
Marketing authorisation holder
Pfizer Limited 

Pfizer Limited
Ramsgate Road
Sandwich
Kent CT13 9NJ
United Kingdom

Marketing authorisation issued
19/12/2006
Revision
8

Assessment history

This page was last updated on

Share this page